Volume 27, Number 3—March 2021
CME ACTIVITY - Research
Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan
Table 3
Demographics and clinical characteristics of household contacts exposed to drug-resistant tuberculosis free of disease at baseline in study of preventive therapy in Karachi, Pakistan, February 2016–March 2017*
Characteristic | No. (%) or median [IQR] |
|||
---|---|---|---|---|
Total, n = 789† | On PT, n = 172 | Did not start PT, n = 43 | Not eligible for PT, n = 574 | |
Age group, y | 19 [10–32] | 7 [3–15] | 16 [3–22] | 24 [15–36] |
<15 | 283 (36) | 128 (74) | 21 (49) | 134 (23) |
>15 |
506 (64) |
44 (26) |
22 (51) |
440 (77) |
Sex | ||||
M | 423 (54) | 91 (53) | 20 (47) | 312 (54) |
F |
366 (46) |
81 (47) |
23 (53) |
262 (46) |
BMI, kg/m2 |
18.1 [14.8–24.0], n = 616 |
14.8 [13.4–16.9], n = 171 |
15.2 [13.4–16.9], n = 42 |
21.6 [17.1–26.0], n = 403 |
Presence of symptoms | n = 737 | n = 172 | n = 43 | n = 522 |
Cough, duration | 10 (1) | 3 (2) | 2 (5) | 5 (1) |
Fever | 7 (1) | 1 (1) | 3 (7) | 3 (1) |
Weight loss |
12 (2) |
1 (1) |
2 (5) |
9 (2) |
Additional TB risk factors | n = 737 | n = 172 | n = 43 | n = 522 |
History of TB | 9 (1) | 0 (0) | 0 (0) | 9 (2) |
TST >5 mm | 6/136 (4) | 6/64 (9) | 0/11 (0) | 0/61 (0) |
Index patient resistant to FQ |
138 (19) |
16 (9) |
11 (26) |
111 (21) |
Regimen given | ||||
Levofloxacin/ethambutol | NA | 102 (59) | NA | NA |
Levofloxacin/ethionamide | NA | 54 (31) | NA | NA |
Moxifloxacin/ethambutol | NA | 11 (6) | NA | NA |
Moxifloxacin/ethionamide |
NA |
5 (3) |
NA |
NA |
TB disease occurred during follow-up |
2 (0.3) |
2 (1) |
0 |
0 |
*FQ, fluoroquinolone; NA, not applicable; PT, preventive therapy; TB, tuberculosis; TST, tuberculin skin test. †Excluding 3 contacts found to have TB and 8 already on treatment for TB at time of screening. |
1These authors contributed equally to this article.